The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 03, 2015

Filed:

Oct. 21, 2009
Applicants:

Stewart Kroll, Oakland, CA (US);

Mark Matteucci, Portola Valley, CA (US);

Charles P. Hart, Mountain View, CA (US);

Jian-xin Duan, South San Francisco, CA (US);

Karen Curd, Burlingame, CA (US);

Inventors:

John G. Curd, Burlingame, CA (US);

Stewart Kroll, Oakland, CA (US);

Mark Matteucci, Portola Valley, CA (US);

Charles P. Hart, Mountain View, CA (US);

Jian-Xin Duan, South San Francisco, CA (US);

Assignee:

Threshold Pharmaceuticals, Inc., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01N 57/00 (2006.01); A61K 31/675 (2006.01); A01N 57/26 (2006.01); A61K 31/66 (2006.01); A61K 9/00 (2006.01); A61K 31/337 (2006.01); A61K 31/4985 (2006.01); A61K 31/513 (2006.01); A61K 31/555 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01); A61K 33/24 (2006.01); A61K 45/06 (2006.01); A61K 47/26 (2006.01); A61K 31/519 (2006.01);
U.S. Cl.
CPC ...
A61K 31/675 (2013.01); A61K 9/0019 (2013.01); A61K 31/337 (2013.01); A61K 31/4985 (2013.01); A61K 31/513 (2013.01); A61K 31/555 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 33/24 (2013.01); A61K 45/06 (2013.01); A61K 47/26 (2013.01); A61K 31/519 (2013.01);
Abstract

Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy.


Find Patent Forward Citations

Loading…